alphaGalCer-RBD is a self-adjuvanting lipoprotein conjugate. alphaGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. alphaGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. alphaGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. alpha-Galactosylceramide (alphaGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain
Molekulargewicht:
1119.60
Formel:
C60H118N4O14
Target-Kategorie:
SARS-CoV
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
